Stock Code: 000028/200028 Notice No.: 2021 -34
Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.
Summary of Semi-Annual Report 2021
I. Important Notice
The summary of semi-annual report is excerpted from the full text of the semi-annual report. For the details, investors should
carefully read the full text of the semi-annual report published on Juchao Information website (www.cninfo.com.cn) and Shenzhen
Stock Exchange Website etc., appointed by CSRC.
Other directors attending the Meeting for semi-annual report deliberation except for the followed
Name of director absent Title for absent director Reasons for absent Attorney
Prompt of modified auditing opinion
□ Applicable √ Not applicable
Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reporting
period
□ Applicable √ Not applicable
The Company plans not to carry out cash dividend and bonus distribution and capitalizing of common reserves
Profit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period
□ Applicable √ Not applicable
II. Basic information of the company
1. Company profile
Short form of the stock Sinopharm Accord, Accord B Stock code 000028, 200028
Stock exchange for listing Shenzhen Stock Exchange
Person/Way to contact Secretary of the Board Rep. of security affairs
Name Chen Changbing Wang Zhaoyu
Accord Pharm. Bldg., No. 15, Ba Gua Si Accord Pharm. Bldg., No. 15, Ba Gua Si
Office add. Road, Futian District, Shenzhen, Guangdong Road, Futian District, Shenzhen, Guangdong
Province Province
Tel. +(86)755 25875195 +(86)755 25875222
E-mail gyyzinvestor@sinopharm.com gyyz0028@sinopharm.com
2. Main financial data and index
Whether it has retroactive adjustment or re-statement on previous accounting data
1
□ Yes √ No
Increase/decrease in this
Current Period Same period of last year
report y-o-y
Operating revenue (RMB) 33,163,091,887.39 27,169,940,188.52 22.06%
Net profit attributable to shareholders of
741,445,013.25 643,451,580.59 15.23%
the listed Company (RMB)
Net profit attributable to shareholders of
the listed Company after deducting 720,954,408.22 627,017,019.45 14.98%
non-recurring gains and losses (RMB)
Net cash flow arising from operating
1,229,373,283.57 1,438,204,043.35 -14.52%
activities (RMB)
Basic earnings per share (RMB/Share)
1.73 1.50 15.33%
(note 1)
Diluted earnings per share (RMB/Share) 1.73 1.50 15.33%
Weighted average ROE Increase 0.31 percentage p
5.22% 4.91%
oints
Increase/decrease in this
End of current period End of last period report-end over that of last
period-end (+,-)
Total assets (RMB) 44,190,878,403.95 39,594,533,471.65 11.61%
Net assets attributable to shareholder of
14,346,870,065.79 13,948,322,652.33 2.86%
listed Company (RMB)
3. Number of shareholders and share-holding
Unit: share
Total preference shareholders
Total common shareholders at with voting rights recovered at
43,600 0
period-end end of reporting period (if
applicable)
Top ten shareholders
Information of shares
Full name of Nature of Proportion of Amount of
Amount of restricted shares held pledged, tagged or frozen
Shareholders shareholder shares held shares held State of share Amount
Sinopharm State-owned
56.06% 239,999,991 5,505,770
Group Co., Ltd. Corporation
FIRST
SENTIER
INVESTORS
GLOBAL
Foreign
UMBRELLA 2.68% 11,469,644
Corporation
FUND PLC -
FSSA CHINA
GROWTH
FUND
Hong Kong
Securities Foreign
2.58% 11,033,948
Clearing Corporation
Company Ltd
2
China National
Pharmaceutical State-owned
1.24% 5,323,043
Foreign Trade Corporation
Corp.
National Social Domestic non
Security Fund state-owned 0.98% 4,200,032
413 Portfolio Corporation
BBH BOS S/A
FIDELITY FD - Foreign
0.78% 3,358,761
CHINA FOCUS Corporation
FD
China
Construction
Bank Domestic non
Corporation state-owned 0.73% 3,111,875
-China Europe Corporation
Value Discovery
Equity Fund
CPIC Fund
-China Pacific
Life Insurance
Co., Ltd. -
with-profit
insurance- CPIC
Fund China Domestic non
Pacific Life state-owned 0.66% 2,822,801
Equity Relative Corporation
Income
(Guaranteed
Dividend)
single assets
management
plan
Fidelity
Investment
Management Foreign
0.54% 2,308,237
(Hong Kong) Corporation
Limited -
Client’s fund
VANGUARD
EMERGING
Foreign
MARKETS 0.41% 1,756,387
Corporation
STOCK INDEX
FUND
Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have
Explanation on associated the same actual controller, which is China National Pharmaceutical Group Corporation. It is
relationship among the aforesaid unknown that there exists no associated relationship or belongs to the consistent actionist among
shareholders the other tradable shareholders regulated by the Management Measure of Information Disclosure
on Change of Shareholding for Listed Companies.
4. Changes of controlling shareholders or actual controller
Changes of controlling shareholders in reporting period
□ Applicable √ Not applicable
Changes of controlling shareholders had no change in reporting period.
Changes of actual controller in reporting period
3
□ Applicable √ Not applicable
Changes of actual controller had no change in reporting period.
5. Total preferred stock shareholders of the Company and shares held by top ten shareholders with
preferred stock held
□ Applicable √ Not applicable
The Company had no shareholders with preferred stock held in the reporting.
6. Bonds in existence as of the approval date of the semi-annual report
□ Applicable √ Not applicable
III. Important events
Nil
4
